{'52WeekChange': 1.6153846,
 'SandP52WeekChange': 0.0644362,
 'address1': '55 Park Lane',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 9.43,
 'askSize': 1800,
 'averageDailyVolume10Day': 616100,
 'averageVolume': 289966,
 'averageVolume10days': 616100,
 'beta': 1.251744,
 'beta3Year': None,
 'bid': 9.26,
 'bidSize': 1300,
 'bookValue': -0.2,
 'category': None,
 'circulatingSupply': None,
 'city': 'London',
 'companyOfficers': [],
 'country': 'United Kingdom',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 9.8,
 'dayLow': 9,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -25.833,
 'enterpriseToRevenue': None,
 'enterpriseValue': 256163952,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 7.372286,
 'fiftyTwoWeekHigh': 12.61,
 'fiftyTwoWeekLow': 1.54,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 10105328,
 'forwardEps': -0.05,
 'forwardPE': -187,
 'fromCurrency': None,
 'fullTimeEmployees': 8,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.13218,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1572307200,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/tizianalifesciences.com',
 'longBusinessSummary': 'Tiziana Life Sciences Plc, a clinical stage '
                        'biotechnology company, focuses on the discovery and '
                        'development of molecules and related diagnostics to '
                        'treat diseases in oncology and immunology in the '
                        "United Kingdom. The company's product pipeline "
                        'includes Foralumab (TZLS-401), a human anti-CD3 '
                        'monclonal antibody for the treatment of autoimmune '
                        'and inflammatory diseases, such GvHD, ulcerative '
                        "colitis, Crohn's disease, multiple sclerosis, type-1 "
                        'diabetes, inflammatory bowel diseases, psoriasis, and '
                        'rheumatoid arthritis; and Milciclib (TZLS-201), which '
                        'is an orally bioavailable, small molecule inhibitor '
                        'of cyclin-dependent kinases and Src family kinases '
                        'for the treatment of hepatocellular carcinoma. It '
                        'also develops Anti IL-6r (TZLS-501), a human '
                        'anti-interleukin-6 receptor monoclonal antibody for '
                        'the treatment of IL6-induced inflammation, primarily '
                        'to treat hospitalized COVID-19 patients with severe '
                        'respiratory symptoms; and StemPrintER, a multi-gene '
                        'signature assay intended for use in patients '
                        'diagnosed with estrogen-receptor positive ER+/HER2 '
                        'negative breast cancers. The company was founded in '
                        '2013 and is headquartered in London, the United '
                        'Kingdom. Tiziana Life Sciences Plc is a subsidiary of '
                        'Planwise Group Limited.',
 'longName': 'Tiziana Life Sciences PLC',
 'market': 'us_market',
 'marketCap': 360097504,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_261234197',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1577750400,
 'navPrice': None,
 'netIncomeToCommon': -9323000,
 'nextFiscalYearEnd': 1640908800,
 'open': 9,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '44 20 7495 2379',
 'previousClose': 8.8,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 9.8,
 'regularMarketDayLow': 9,
 'regularMarketOpen': 9,
 'regularMarketPreviousClose': 8.8,
 'regularMarketPrice': 9,
 'regularMarketVolume': 302788,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 33281800,
 'sharesPercentSharesOut': 0.0004,
 'sharesShort': 26442,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 88877,
 'shortName': 'Tiziana Life Sciences plc - Ame',
 'shortPercentOfFloat': None,
 'shortRatio': 0.08,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'TLSA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.34,
 'twoHundredDayAverage': 4.1639566,
 'volume': 302788,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.tizianalifesciences.com',
 'yield': None,
 'ytdReturn': None,
 'zip': 'W1K 1NA'}